Purchase Order 75N91020P00662

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for $14,631.00 on June 18, 2020. The order procures biological and reagent materials and carries no set-aside designation. Performance occurs in Auburn, California. The ultimate completion date is July 19, 2020. Firm fixed price applies.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc., for $16,626.00 on January 7, 2020, with an ultimate completion date of February 7, 2021. The order covers a maintenance agreement on firm fixed price terms. No set-aside was used. Place of performance is Auburn, California.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $24,806.85 firm fixed price purchase order to Miltenyi Biotec, Inc. for equipment. The place of performance will be in Auburn, California, and the period of performance is from November 8, 2023 through December 26, 2023. This purchase order was awarded under the National Cancer Institute's research programs to procure equipment that will support the agency's efforts to advance cancer...

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. valued at $22,685.00 for scientific equipment with heaters, with an award date of March 12, 2021 and ultimate completion date of April 12, 2021. Place of performance is Auburn, California. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute issued a purchase order to Miltenyi Biotec, Inc. for $16,626.00, with an award date of January 7, 2020 and ultimate completion date of January 9, 2021. The contract is a firm fixed price maintenance agreement with no set-aside designation. Place of performance is Auburn, California.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute (HHS-NIH-NCI) awarded a $24,806.85 firm fixed price purchase order to Miltenyi Biotec, Inc. for laboratory equipment. The place of performance is Auburn, California and the period of performance is from September 12, 2023 through October 12, 2023. The National Cancer Institute conducts and supports research aimed at discovering prevention and cures for cancer. This purchase order for laboratory...

The National Institute of Nursing Research awarded a purchase order to Miltenyi Biotec, Inc. valued at $13,612.17 on March 25, 2020, with an ultimate completion date of January 14, 2021. The order is a firm fixed price, commercial acquisition with no set-aside designation. Place of performance is Auburn, California. The purchase order procures specialized biotechnology equipment, reagents, and consumables for cell separation, analysis, and processing technologies that support biomedical research...

The National Institute of Neurological Disorders and Stroke awarded a purchase order to Miltenyi Biotec, Inc. valued at $24,990.50 on April 6, 2021. Work is performed in Auburn, California. The order procures specialized biotechnology equipment, reagents, or services supporting cell separation, analysis, and processing technologies for biomedical research and cell therapy development. The purchase order is firm fixed price with no set-aside designation and carries an ultimate completion date...

The Department of Health and Human Services' National Institutes of Health's National Cancer Institute awarded a $18,500 firm fixed price purchase order to Miltenyi Biotec, Inc. of Bethesda, Maryland for services to be completed by January 9, 2025. The award was made on January 10, 2024 under a non-set aside designation to support the NIH NCI's biomedical research mission. Miltenyi Biotec will provide unspecified services to the funding agency in Bethesda, Maryland through January 2025 for the...

This is a $18,450 firm fixed-price purchase order awarded by the National Cancer Institute (NCI) to Miltenyi Biotec, Inc., a global biotechnology company that provides specialized scientific instruments, reagents, and services to support biomedical research, cell therapy development, and clinical translation. The contract is for a service agreement with a completion date of January 9, 2026. Miltenyi Biotec, which is a foreign-owned, for-profit manufacturer, has extensive experience as a prime...